Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Cell Reports

Volumn 8, Issue 3, 2014, Pages 696-706

  Rigamonti, Nicolò ^a   Kadioglu, Ece ^a   Keklikoglou, Ioanna ^a   Rmili, Céline Wyser ^a   Leow, Ching Ching ^b   de Palma, Michele ^a  

^a EPFL   (Switzerland)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3.19.3; MONOCLONAL ANTIBODY DC101; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC CELL; HYPOXIA; MACROPHAGE MIGRATION; MALE; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR RESISTANCE; UPREGULATION;

MOUSE MAMMARY TUMOR VIRUS;

EID: 84924616997     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.06.059     Document Type: Article

References (49)

1. Allen, E., Walters, I.B., and Hanahan, D. (2011). Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res. 17, 5299-5310.
2. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603.
3. Blagoev, K.B., Wilkerson, J., Stein, W.D., Motzer, R.J., Bates, S.E., and Fojo, A.T. (2013). Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Reports 3, 277-281.
4. Brown, J.L., Cao, Z.A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., Zhou, J.Q., Tabrizi, M., Emery, S., McDermott, B., et al. (2010). A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 9, 145-156.
5. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
6. Chung, A.S., Lee, J., and Ferrara, N. (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514.
7. Chung, A.S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Komuves, L., Peale, F., and Ferrara, N. (2012). Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol. 227, 404-416.
8. Claesson-Welsh, L., and Welsh, M. (2013). VEGFA and tumour angiogenesis. J. Intern. Med. 273, 114-127.
9. Daly, C., Pasnikowski, E., Burova, E., Wong, V., Aldrich, T.H., Griffiths, J., Ioffe, E., Daly, T.J., Fandl, J.P., Papadopoulos, N., et al. (2006). Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc. Natl. Acad. Sci. USA 103, 15491-15496.
10. Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A.S., Papadopoulos, N., Kyle, A.H., Minchinton, A.I., Yancopoulos, G.D., and Thurston, G. (2013). Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 73, 108-118.
11. De Palma, M., and Hanahan, D. (2012). The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6, 111-127.
12. De Palma, M., and Lewis, C.E. (2013). Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277-286.
13. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., and Kerbel, R.S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
14. Eklund, L., and Saharinen, P. (2013). Angiopoietin signaling in the vasculature. Exp. Cell Res. 319, 1271-1280.
15. Eroglu, Z., Stein, C.A., and Pal, S.K. (2013). Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin. Investig. Drugs 22, 813-825.
16. Fathers, K.E., Stone, C.M., Minhas, K., Marriott, J.J., Greenwood, J.D., Dumont, D.J., and Coomber, B.L. (2005). Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am. J. Pathol. 167, 1753-1762.
17. Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E.K., et al. (2012). Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 122, 1991-2005.
18. Ferrara, N. (2010). Role of myeloid cells in vascular endothelial growth factorindependent tumor angiogenesis. Curr. Opin. Hematol. 17, 219-224.
19. Gabrusiewicz, K., Liu, D., Cortes-Santiago, N., Hossain, M.B., Conrad, C.A., Aldape, K.D., Fuller, G.N., Marini, F.C., Alonso, M.M., Idoate, M.A., et al. (2014). Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5, 2208-2220.
20. Gerald, D., Chintharlapalli, S., Augustin, H.G., and Benjamin, L.E. (2013). Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 73, 1649-1657.
21. Goede, V., Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T.C., Weihrauch, M.R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010). Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer 103, 1407-1414.
22. Hashizume, H., Falcón, B.L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J.V., Oliner, J.D., and McDonald, D.M. (2010). Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70, 2213-2223.
23. Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., and Augustin, H.G. (2009). Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 15, 1384-1392.
24. Holopainen, T., Saharinen, P., D'Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012). Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 104, 461-475.
25. Huang, H., Lai, J.Y., Do, J., Liu, D., Li, L., Del Rosario, J., Doppalapudi, V.R., Pirie-Shepherd, S., Levin, N., Bradshaw, C., et al. (2011). Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 17, 1001-1011.
26. Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H.H., Martarello, L., et al. (2013). Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 19, 6730-6740.
27. Kim, S., Dobi, E., Jary, M., Monnien, F., Curtit, E., Nguyen, T., Lakkis, Z., Heyd, B., Fratte, S., Cléau, D., et al. (2013). Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in firstline metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer 13, 611.
28. Leow, C.C., Coffman, K., Inigo, I., Breen, S., Czapiga, M., Soukharev, S., Gingles, N., Peterson, N., Fazenbaker, C., Woods, R., et al. (2012). MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol. 40, 1321-1330.
29. Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L.S., Gentner, B., Brown, J.L., Naldini, L., and De Palma, M. (2011). Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526.
30. Minami, T., Jiang, S., Schadler, K., Suehiro, J., Osawa, T., Oike, Y., Miura, M., Naito, M., Kodama, T., and Ryeom, S. (2013). The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Reports 4, 709-723.
31. Monk, B.J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.S., Oaknin, A., Ray-Coquard, I., Provencher, D.M., Karlan, B.Y., et al. (2014). Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 799-808.
32. Oh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., and Honda, Y. (1999). Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274, 15732-15739.
33. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
34. Park, J.H., Park, K.J., Kim, Y.S., Sheen, S.S., Lee, K.S., Lee, H.N., Oh, Y.J., and Hwang, S.C. (2007). Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132, 200-206.
35. Peeters, M., Strickland, A.H., Lichinitser, M., Suresh, A.V., Manikhas, G., Shapiro, J., Rogowski, W., Huang, X., Wu, B., Warner, D., et al. (2013). A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br. J. Cancer 108, 503-511.
36. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., et al. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209-5218.
37. Rigamonti, N., and De Palma, M. (2013). A role for angiopoietin-2 in organ-specific metastasis. Cell Reports 4, 621-623.
38. Rini, B., Szczylik, C., Tannir, N.M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L.Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012). AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118, 6152-6161.
39. Rivera, L., Pandika, M., and Bergers, G. (2014). Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Adv. Exp. Med. Biol. 772, 83-99.
40. Sennino, B., and McDonald, D.M. (2012). Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 12, 699-709.
41. Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R.M., Williamson, C.W., Bhagwandin, V., Tabruyn, S.P., You, W.K., Chapman, H.A., Christensen, J.G., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2, 270-287.
42. Shojaei, F., Singh, M., Thompson, J.D., and Ferrara, N. (2008). Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl. Acad. Sci. USA 105, 2640-2645.
43. Singh, M., Couto, S.S., Forrest, W.F., Lima, A., Cheng, J.H., Molina, R., Long, J.E., Hamilton, P., McNutt, A., Kasman, I., et al. (2012). Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol. 227, 417-430.
44. Spratlin, J.L., Cohen, R.B., Eadens, M., Gore, L., Camidge, D.R., Diab, S., Leong, S., O'Bryant, C., Chow, L.Q., Serkova, N.J., et al. (2010). Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780-787.
45. Van der Veldt, A.A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M.P., Greuter, H.N., Hendrikse, N.H., Eriksson, J., Windhorst, A.D., Postmus, P.E., et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82-91.
46. Vasudev, N.S., and Reynolds, A.R. (2014). Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494.
47. Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147.
48. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.
49. Yoon, S.S., Duda, D.G., Karl, D.L., Kim, T.M., Kambadakone, A.R., Chen, Y.L., Rothrock, C., Rosenberg, A.E., Nielsen, G.P., Kirsch, D.G., et al. (2011). Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 81, 1081-1090.